References
- Haisa M, Kashino S, Kawai R, Maeda H. The monoclinic form of p-hydroxyacetanilide. Acta Cryst 1976; B32: 1283–1285, Boldyrev VV, Vasil'chenko MA, Shakhtshneider TP; Naumov DYu, Boldyreva, EV. Etch pits morphology on p-hydroxyacetanilide single crystals. Solid State Ionics 1997; 101–103, 869–874
- Nichols G, Frampton CS. Physicochemical characterization of the orthorhombic polymorph of paracetamol crystallized from solution. J Pharm Sci 1998; 87: 684–693
- Haisa M, Kashino S, Maeda H. The orthorhombic form of p-hydroxyacetanilide. Acta Cryst 1974; B30: 2510–2512
- Di Martino P, Guyot-Hermann AM, Conflant P, Drache M, Guyot JC. A new pure paracetamol for direct compression: The orthorhombic form. Int J Pharm 1996; 128: 1–8, Joiris E, Di Martino P, Berneron C, Guyot-Hermann AM, Guyot JC. Compression behaviour of orthorhombic paracetamol. Pharm. Res. 1998; 15, 1122–1130
- Burger A. Zur interpretation von polymorphie-untersuchungen. Acta Pharm Tech 1982; 28: 1–20
- Leadbeater C. Glaxo fights for zantac patent. 1991, Financial Times, 1991; Tuesday, April 9.
- Chemburkar SR, Bauer J, Deming K, Spiwek H, Patel K, Morris J, Henry R, Spanton S, Dziki W, Porter W, Quick J, Bauer P, Donaubauer J, Narayanan BA, Soldani M, Riley D, McFarland K. Dealing with the impact of ritonavir polymorphs on the late stages of bulk drug process development. Org Proc Res Dev 2000; 4: 413–417
- Plastas-Iglesias C, Corsi DM, Elst LV, Muller RN. Stability, structure and dynamics of cationic lanthanide (III) complexes of N,N'-bis(propylamido)ethylenediamine-N,N'-diacetic acid. Dalton Trans 2003; 727–737
- Kelleher JM, Lawrence SE, Moynihan HA. Effect of the steric demand and hydrogen bonding capacity of additives on the crystal polymorphism of sulfathiazole. CrystEngComm 2006; 8: 327–332
- Kelleher JM, Lawrence SE, McAuliffe MT, Moynihan HA. Monomeric and polymeric derivatives of 5-aminoisophthalic acid as selective inhibitors of the beta-polymorph of l-glutamic acid. CrystEngComm 2007; 9: 72–77
- Moynihan HA, O'Hare IP. Spectroscopic characterisation of orthorhombic and monoclinic paracetamol. Int J Pharm 2002; 247: 179–185
- Lagas M, Lerk CF. The polymorphism of sulphathiazole. Int J Pharm 1981; 8: 11–24, Hughes DS, Hursthouse MB, Threlfall T, Travener S. A new polymorph of sulfathiazole. Acta Cryst. C, 1999; 55, 1831–1833
- Blagden N, Davey RJ, Rowe R, Roberts R. Disappearing polymorphs and the role of reaction by-products: The case of sulphathiazole. Int J Pharm 1998; 172: 169–177, Bladgen N. Crystal engineering of polymorph appearance: the case of sulphathiazole. Powder Technol 2001; 121, 46–52
- Blagden N, Davey RJ, Lieberman HF, Williams L, Payne R, Roberts R, Rowe R, Docherty R. Crystal chemistry and solvent effects in polymorphic systems - Sulfathiazole. J Chem Soc Faraday Trans 1998; 94: 1035–1044
- Yu L, Reutzel-Edens SM, Mitchell CA. Crystallization and polymorphism of conformationally flexible molecules: Problems, patterns and strategies. Org Proc Res Dev 2000; 4: 396–402
- Lehmann MS, Nunes AC. A short hydrogen-bond between near identical carboxyl groups in the alpha modification of l-glutamic acid. Acta Crystallogr 1980; B36: 1621–1625
- Kitamura M. Polymorphism in the crystallization of l-glutamic acid. J Cryst Growth 1989; 96: 541–546
- Davey RJ, Blagden N, Potts GD, Docherty R. Polymorphism in molecular crystals: Stabilization of a metastable form by conformational mimicry. J Am Chem Soc 1997; 119: 1767–1772
- Staab E, Addadi L, Leiserowitz L, Lahav M. Control of polymorphism by ‘tailor-made’ polymeric crystallization auxiliaries. Preferential precipitation of a metastable polar form for second harmonic generation. Adv Mater 1990; 2: 40
- Hendriksen BA, Grant DJW. The effects of structurally related substances on the nucleation kinetics of paracetamol (acetaminophen). J Cryst Growth 1995; 156: 252–260